Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $47M (down 10.2% year over year) with net income of −$18M.
Q1 2026 key financials · XBRL
- Revenue
- $47M
- −10.2% YoY
- Net income
- −$18M
- −12.8% YoY
- Operating margin
- -36.4%
- Gross margin
- 79.3%
- EPS (diluted)
- −$0.28
- −12.0% YoY
Source: XBRL data from the TREACE MEDICAL CONCEPTS, INC. (TMCI) Q1 2026 10-Q on SEC EDGAR. USD.
TREACE MEDICAL CONCEPTS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $47.2M, down 10.2% YoY from $52.6M, driven by lower kit volume and mix toward lower-priced minimally invasive kits
- Gross margin 79.3% vs 79.7% YoY; net loss $18.0M vs $15.9M
- Lapiplasty flagship kits underperformed as minimally invasive kits gained adoption at lower average selling prices
- Cash $9.5M plus marketable securities $42.3M; term loan principal $60.0M
- Operating cash flow $7.2M vs $4.2M YoY; investing cash use $7.8M vs $1.9M
- Near-term headwinds: macroeconomic pressures, competition, lower reimbursements, and shifting preference toward ambulatory surgery centers
Risk Factors
- No risk-factors section provided in the submitted filing text
- No newly added risk or 10-K comparison disclosed
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TREACE MEDICAL CONCEPTS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.